Evaxion Biotech A/S (EVAX): history, ownership, mission, how it works & makes money

A Brief History of Evaxion Biotech A/S (EVAX)

Company Formation and Early Development

Evaxion Biotech A/S was founded in 2016 and is headquartered in Copenhagen, Denmark. The company specializes in artificial intelligence-driven immunotherapy for the treatment of various cancers and infectious diseases.

Funding and Financial Milestones

In 2018, Evaxion Biotech secured a funding round, raising approximately €5 million ($5.7 million) led by several investors, including Sunstone Capital. The company has since raised a total of over €40 million ($46 million) through funding rounds and public offerings.

Public Offering

Evaxion went public on NASDAQ First North Growth Market in April 2021, achieving a market capitalization of around €140 million ($162 million) on the initial day of trading.

Key Developments and Partnerships

In 2020, Evaxion entered into a strategic partnership with the U.S. National Cancer Institute to develop cancer vaccines using its proprietary AI technology.

Product Pipeline

Evaxion has several products in its pipeline:

• EVX-01: A personalized cancer vaccine currently in clinical trials.
• EVX-02: A vaccine candidate targeting the treatment of solid tumors.
• EVX-03: A therapeutic vaccine for the treatment of bacterial infections.

Recent Financial Performance

As of 2023, Evaxion reported a revenue of DKK 12 million ($1.8 million) with a net loss of DKK 45 million ($6.8 million) for the financial year. The company’s total assets were valued at DKK 120 million ($18 million) at the end of Q1 2023.

Clinical Trials and Regulatory Approvals

Evaxion is currently conducting Phase I clinical trials for its EVX-01 vaccine with an expected completion date in late 2023. Results from preliminary studies showed a positive immune response in 75% of participants.

Future Outlook

The company anticipates further advancements in its product pipeline and aims to continue its collaboration with research institutions. The projected market for immunotherapy is expected to reach $125 billion by 2024, indicating significant growth opportunities for Evaxion Biotech.

A Who Owns Evaxion Biotech A/S (EVAX)

Ownership Structure

The ownership of Evaxion Biotech A/S is characterized by a mix of institutional and retail investors. As of the latest available data from October 2023, the shareholding structure is as follows:

Major Shareholders

The following table outlines the major shareholders of Evaxion Biotech A/S, including their respective ownership stakes:

Recent Financial Data

As of Q3 2023, Evaxion Biotech A/S reported the following financial figures:

• Market Capitalization: €250 million
• Revenue for Q2 2023: €12 million
• Net Loss for Q2 2023: €3 million
• Cash Reserves: €35 million

Stock Performance

The stock performance of Evaxion Biotech A/S has been notable in recent months:

• Stock Price as of October 2023: €3.50
• 52-Week High: €5.00
• 52-Week Low: €2.50
• Year-to-Date Performance: +15%

Future Projections

Analysts predict the following for Evaxion Biotech A/S:

• Projected Revenue Growth for 2024: 20%
• Expected R&D Investment for 2024: €15 million
• Target Stock Price for 2024: €4.50

Evaxion Biotech A/S (EVAX) Mission Statement

Core Purpose

The mission of Evaxion Biotech A/S is to leverage advanced artificial intelligence and machine learning technologies to revolutionize the development of immunotherapies, aiming to combat various cancers and infectious diseases effectively.

Strategic Goals

• Product Development: Focus on developing personalized cancer vaccines and therapies based on individual patient profiles.
• Market Expansion: Target global markets, including Europe and North America, enhancing accessibility to cutting-edge therapies.
• Partnerships: Establish collaborations with research institutions and pharmaceutical companies to bolster innovation and reduce time-to-market.
• Financial Sustainability: Achieve significant revenue growth by 2025, aiming for an estimated revenue of approximately €50 million.

Recent Achievements

Evaxion Biotech A/S has reported advancements in its clinical trials, reflecting progress in its mission statement. As of Q3 2023, the company has initiated Phase 2 clinical trials for its lead product candidate, EVX-01, targeting malignant melanoma.

Financial Overview

Target Audience

Evaxion Biotech primarily targets:

• Oncology patients seeking novel treatment options.
• Healthcare providers looking for innovative therapies.
• Investors interested in biotech advancements and market growth.

Future Directions

Evaxion Biotech's strategic roadmap includes:

• Enhancing AI Algorithms: Continuously improve AI-driven models for better predictive capabilities in immunotherapy responses.
• Expanding Product Pipeline: Develop additional vaccine candidates targeting various cancers and infectious diseases.
• Increasing Clinical Engagement: Foster patient engagement programs to facilitate clinical trial participation.

Conclusion of Mission Focus

Evaxion Biotech A/S remains committed to its mission, focusing on innovation, patient-centric solutions, and sustainable financial growth as it navigates the evolving landscape of biopharmaceuticals.

How Evaxion Biotech A/S (EVAX) Works

Company Overview

Evaxion Biotech A/S (EVAX) is a biotechnology company based in Denmark that specializes in the development of immunotherapy and vaccine candidates using its proprietary artificial intelligence (AI) platform. The company's innovative approach aims to enhance the identification of new therapeutic targets and vaccine candidates.

Business Model

Evaxion operates on a partnership and collaborative model, engaging with pharmaceutical companies and research institutions to advance its pipeline products. The main revenue sources include:

• Collaboration agreements
• Licensing deals
• Grants and funding for research projects

Technology Platform

Evaxion utilizes a unique AI platform called EPIC (Evaxion Platform for Immunotherapy and Vaccines) that predicts the immunogenicity of potential vaccine candidates. This platform processes vast datasets to identify targets that can initiate a strong immune response.

Pipeline Products

As of October 2023, Evaxion's clinical pipeline includes several promising candidates:

Financial Performance

In the latest financial report for Q3 2023, Evaxion Biotech A/S reported:

• Revenue: €2.7 million
• Net Income: €-1.2 million
• Operating Loss: €1.5 million
• Cash Reserves: €10.5 million

Market Position

Evaxion operates in a competitive biotechnology landscape, focusing on the following:

• Strategic partnerships with larger pharmaceutical companies.
• Investment in R&D for novel therapies.
• Intellectual property management to protect proprietary technology.

Regulatory Landscape

The company navigates complex regulatory requirements, including:

• FDA approval for clinical trials in the United States.
• EMA guidelines for the European market.
• Collaboration with regulatory bodies for expedited review processes.

How Evaxion Biotech A/S (EVAX) Makes Money

Revenue Streams

Evaxion Biotech A/S generates revenue through several key avenues:

• Partnerships and Collaborations
• Research Funding
• Licensing Agreements
• Product Sales

Partnerships and Collaborations

Partnerships with larger pharmaceutical companies provide significant funding and resources. Notable collaborations include:

• Partnership with Merck & Co. for the development of cancer immunotherapies
• Collaboration with the University of Copenhagen for research projects

In its most recent fiscal year, Evaxion reported receiving €2 million in partnership funding.

Research Funding

Evaxion actively pursues public and private research grants. In 2022, they received €1.5 million from the Horizon 2020 program aimed at innovative research projects in biotechnology.

Licensing Agreements

Through licensing agreements, Evaxion monetizes its proprietary technologies and drug candidates. For example, licensing their AI-powered platform for vaccine development has yielded:

• €500,000 in upfront fees in 2022
• Potential milestones of up to €10 million from future project developments

Product Sales

As Evaxion progresses towards bringing products to market, sales will become a more significant revenue source. Currently, their pipeline includes:

• EVX-01, a cancer immunotherapy
• EVX-02, a vaccine candidate for bacterial infections

Projected revenues from these products in early commercialization stages are estimated to reach €3 million by 2025.

Financial Overview

The financial performance of Evaxion Biotech A/S can be summarized by the following table:

Market Position and Future Prospects

Evaxion Biotech operates in a competitive biotech landscape, focusing on innovative AI-driven solutions. As of October 2023, their market capitalization stands at approximately €50 million.

The company's goal is to leverage its technology for faster development timelines in drug discovery, which could significantly impact future revenues.

Summary of Key Financial Metrics

The following table highlights important financial metrics relevant to investors:

Conclusion of Financial Insights

The financial data demonstrates a growing trend in revenue aligned with strategic partnerships and product advancement. As Evaxion continues to develop its pipeline, financial performance is expected to improve.